Acura Pharmaceuticals, Inc. (ACUR)

0.0041 +0.0011 (+36.67%) 收市：03:39PM EDT

Acura Pharmaceuticals, Inc.

616 N. North Court
Suite 120
Palatine, IL 60067
United States
847 705 7709
https://www.acurapharm.com

版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 9

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Robert B. Jones	CEO, President & Director	150k	無	1959
Mr. Peter A. Clemens	Senior VP, CFO & Secretary	200k	無	1953
Mr. Robert A. Seiser CPA, Ph.D.	VP, Treasurer & Corporate Controller	210.2k	3.24k	1964

截止 2021年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. operates as a subsidiary of Abuse Deterrent Pharma, LLC.

公司管治

截至 無 止，Acura Pharmaceuticals, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。